Summits

Improving MDS Outcomes from Diagnosis to Treatment: A Multidisciplinary Approach
A Complimentary CME Summit on Myelodysplastic Syndrome (MDS)

Hosted by American Society for Clinical Pathology (ASCP), American Society of Hematology (ASH), and The France Foundation

The goal of this summit is to improve performance diagnosis and treatment of MDS patients. Participants will actively engage in multidisciplinary, interactive small-group activities, including: 

Case-based tumor board discussions
4 Break Out Sessions covering

  • Assessing low or high grade MDS
  •  Acquiring of morphologic mimics
  • Applying the prognostic scoring system to cytogenetics
  • Identifying the new role of molecular testing

Team Based Case Analysis and Presentation
Learning Objectives:

  • Recognize the importance and indications for using certain tests when considering a diagnosis of MDS
  • Identify and utilize MDS classification systems based on morphological, clinical, and cytogenetic criteria
  • Utilize prognostic scoring systems in MDS patients and how to apply them
  • Identify the impact of gene 5q deletion, 5q-, haploinsufficiency and allele RPS14 on diagnosis and treatment of MDS.
  • Recognize commonly overlooked or misinterpreted MDS patient characteristics
  • Delineate important aspects of bone marrow specimen acquisition, preparation, and transport that impact the accuracy of pathologist interpretation
  • Review and compare key components of available tools for MDS classification and risk stratification
  • Describe a detailed multifactorial assessment that takes into account the individual characteristics of the patient with MDS when considering treatment options
  • Explain common comorbidities associated with MDS and how they can affect disease management and outcomes
  • Formulate an MDS management plan that includes scheduled time for discussions with the patient, important aspects of care to discuss, and referral to patient education resources 
  • Apply best practices in communications between the clinical care team to ensure optimal diagnosis and treatment for patients with MDS from screening to ongoing post treatment evaluation
 
Who should attend:
Pathologists, Hematopathologists, Medical Laboratory Scientists, Hematologists, Medical Oncologists, Pathologists' Assistants, Hematology & Oncology Nurse Practitioners & Physician Assistants.

Workshop designed to bridge practice gaps in Myelodysplastic Syndrome (MDS) diagnosis and classification for multidisciplinary teams representing hematologists, oncologists, pathologists and hematopathologists to achieve enhanced patient outcomes.

The program will offer online post-workshop reinforcement activities including MDS CheckPath Simulations and 4-Multimedia MDS Cases featuring Hematologist, Oncologists & Pathologist teams.

 

Click here to review the agenda.

  LOCATIONS  
   


Austin, TX
 
November 4, 2016
 
MDS Faculty:
Tracy I. George, MD
Marilyn L. Slovak, PhD, FACMG
William Koss, MD
Arundhati Rao, MD, PhD
Guillermo Garcia-Manero, MD
Elias Jabbour, MD



San Diego, CA
 
December 3-6, 2016
ASH Annual Meeting
MDS Faculty:
Mikkael A. Sekeres, MD, MS
David P. Steensma, MD
Tracy I. George, MD
Marilyn L. Slovak, PhD, FACMG



 

  MDS Summit
8:00 AM–2:30 PM
 
   
8:00–8:15 AM Registration and Breakfast
8:15–8:30 AM Welcome, Introductions & Summit Overview
8:30–9:30 AM Tumor Board Presentation
9:30–9:45 AM Break
9:45–11:45 AM BREAKOUT ROTATIONS
NOTE: ROTATIONS ARE EVERY 30 MINUTES
  Breakout #1: Higher Risk, Lower Risk
Breakout #2: Morphologic Mimics
Breakout #3: Cytogenetics: Applying the Prognostic Scoring System
Breakout #4: The Role of Molecular Testing
11:45 AM –12:15 PM Lunch
12:15–1:15 PM PBL Workgroup Discussion & Presentation Preparation
1:15–2:15 PM PBL Presentations from Workgroups/Q&A
2:15-2:30 PM Summit Wrap-up